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FLT1 and transcriptome-wide 
polyadenylation site (PAS) analysis 
in preeclampsia
Ami Ashar-Patel1, Yasin Kaymaz  2, Augustine Rajakumar  4,5, Jeffrey A. Bailey2,3, S. Ananth 
Karumanchi5 & Melissa J. Moore1
Maternal symptoms of preeclampsia (PE) are primarily driven by excess anti-angiogenic factors 
originating from the placenta. Chief among these are soluble Flt1 proteins (sFlt1s) produced from 
alternatively polyadenylated mRNA isoforms. Here we used polyadenylation site sequencing (PAS-Seq) 
of RNA from normal and PE human placentae to interrogate transcriptome-wide gene expression and 
alternative polyadenylation signatures associated with early-onset PE (EO-PE; symptom onset < 34 
weeks) and late-onset PE (LO-PE; symptom onset > 34 weeks) cohorts. While we observed no general 
shift in alternative polyadenylation associated with PE, the EO-PE and LO-PE cohorts do exhibit gene 
expression profiles distinct from both each other and from normal placentae. The only two genes 
upregulated across all transcriptome-wide PE analyses to date (microarray, RNA-Seq and PAS-Seq) 
are NRIP1 (RIP140), a transcriptional co-regulator linked to metabolic syndromes associated with 
obesity, and Flt1. Consistent with sFlt1 overproduction being a significant driver of clinical symptoms, 
placental Flt1 mRNA levels strongly correlate with maternal blood pressure. For Flt1, just three mRNA 
isoforms account for > 94% of all transcripts, with increased transcription of the entire locus driving 
Flt1 upregulation in both EO-PE and LO-PE. These three isoforms thus represent potential targets for 
therapeutic RNA interference (RNAi) in both early and late presentations.
Preeclampsia (PE) is one of the three leading causes of premature birth1. Characterized by hypertension and 
proteinuria in the third trimester, PE complicates up to 10% of pregnancies, and is estimated to result in more 
than 76,000 maternal and 500,000 infant deaths each year worldwide (www.preeclampsia.org). In the developed 
world, significant resources are dedicated to the identification and management of preeclampsia, with US health 
care costs estimated to be 40–100 times higher for early-onset preeclamptic deliveries than for uncomplicated 
term deliveries2. PE is a highly heterogeneous disease that initiates in the placenta and is likely driven by mul-
tiple mechanisms3,4. In particular, early onset PE (EO-PE; defined by symptom onset < 34 weeks) is thought to 
be clinically distinct from late onset PE (LO-PE; defined by symptom onset > 34 weeks)5–9. EO-PE is thought to 
be driven by poor placentation during early development, whereas LO-PE is considered to be a more maternal 
syndrome10.
Although the root causes of PE are not fully understood, it is now well established that the clinical manifesta-
tions are due to excess anti-angiogenic proteins, primarily “soluble fms-like tyrosine kinase 1” proteins (sFlt1s) 
in the mother’s bloodstream11. sFlt1s are truncated forms of the membrane-bound vascular endothelial growth 
factor (VEGF) receptor FLT1 (aka, VEGFR1) that normally function to buffer placental growth factor (PlGF) and 
VEGF signaling. sFlt1s contain the extracellular binding domain present in full length or membrane-bound FLT1 
(mFlt1), but are secreted because they lack the transmembrane and intracellular tyrosine kinase domains. When 
sFlt1s are abnormally high in the mother’s circulatory system, they interfere with her body’s ability to respond to 
VEGF. Among other functions, VEGF is required for maintenance of the hepatic sinusoidal vasculature and other 
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA. 2Program in 
Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Boston, MA, USA. 3Division of 
Transfusion Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. 
4Departments of Gynecology and Obstetrics, Emory University, Atlanta, USA. 5Departments of Medicine, Obstetrics 
and Gynecology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard 
Medical School, Boston, MA, USA. Correspondence and requests for materials should be addressed to M.J.M. (email: 
melissa.moore@umassmed.edu)
Received: 11 April 2017
Accepted: 25 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC RepoRts | 7: 12139  | DOI:10.1038/s41598-017-11639-6
fenestrated vascular beds in the body12. Breakdown of these structures impairs maternal kidney function, leading 
to hypertension, proteinuria and cerebral edema13–15 – classic features of PE and eclampsia.
In mammals, FLT1 is predominantly expressed in the placenta, with human placental Flt1 mRNA levels being 
40–50 times higher than those observed in any other adult tissue16 (Fig. 1a). Whereas the full-length isoform 
predominates in most adult tissues, placental and liver expression are dominated by truncated isoforms due to 
alternative polyadenylation (Fig. 1b). These alternative polyadenylation sites occur within introns downstream 
of the exons encoding the extracellular binding domain but upstream of those encoding the transmembrane 
and intracellular signaling domains17–19. Five different sFlt1 mRNA isoforms have been reported to date20. 
Two (sFlt1-i13-short and sFlt1-i13-long) result from alternative polyadenylation at different sites in intron 
13 to yield mRNAs encoding the same 687 amino acid sFlt1 protein isoform, but with either a 17 or 4146 nt 
3′-UTR(Untranslated region), respectively. Three others (sFlt1-i14, sFlt1-e15a and sFlt1-e15b) are due to alter-
native polyadenylation within intron 14. sFlt1-e15a and sFlt1-e15b result from activation of two different cryptic 
splice acceptors (cryptic 3′ splice sites) upon use of alternative polyadenylation sites in the latter half of intron 14. 
In all, these five sFlt1 mRNAs encode four different sFlt1 proteins with different C-termini.
In women with PE, circulating sFlt1 protein levels are 5 to 7 times higher than those observed in normal preg-
nancies20–22. One potential therapeutic approach would be to selectively knock down sFlt1 expression by RNA 
silencing (RNA interference, RNAi) using short interfering RNAs (siRNAs) targeting sequences unique to the 
sFlt1 mRNA isoforms and not contained in mFlt1 mRNA (manuscript in preparation). Success of this strategy 
requires knowing exactly which sFlt1 mRNA isoforms to target. Further, while circulating sFlt1 levels increase in 
both EO-PE and LO-PE, this increase starts earlier in EO-PE and often with a more aggressive trajectory23. This 
raises the question of whether EO-PE placentae express a different pattern of sFlt1 mRNA isoforms than LO-PE 
Figure 1. FLT1 expression and patient selection. (a) Mean RNA-Seq FLT1 gene expression in various human 
tissues. Expression values are given as Fragments Per Kilobase of transcript per Million reads (FPKM) (n = 2–7; 
whisker: standard deviation). (b) RNA-Seq data for FLT1 gene illustrating isoform differences across various 
tissues. All data in (a and b) are from http://v14.proteinatlas.org./ENSG00000102755-FLT1/tissue. (c) Patient 
segmentation into three groups by maternal systolic blood pressure and serum sFlt1: PlGF: Normal (CTRL, 
green, n = 6), Early-Onset PE (EO-PE, red, n = 8), and Late-Onset PE (LO-PE, blue, n = 3).
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placentae. That is, is it possible to define a common set of sFlt1 mRNA isoforms suitable for therapeutic interven-
tion in both EO-PE and LO-PE patients?
Here we applied polyadenylation site sequencing (PAS-Seq) method on RNA isolated from normal (CTRL) 
and PE human placentas to identify the most abundant sFlt1 mRNA isoforms. Because PAS-Seq specifically 
interrogates polyadenylation sites it provides a much more accurate assessment of transcript 3′ ends than 
RNA-Seq24–26, which is generally biased toward transcript 5′ ends and is a better for investigating alternative 
splicing pattern27,28. Like RNA-Seq, PAS-Seq can be used for differential gene expression analysis by combining 
all isoforms detected at an individual gene locus into a single gene expression number24. Therefore, in addition 
to quantifying alternative polyadenylation both at the Flt1 locus and transcriptome-wide, our PAS-Seq data also 
allowed us to investigate overall gene expression changes between our patient groups.
Results
Placental PAS-Seq datasets. Several risk factors are associated with PE29–31. In an attempt to minimize 
confounding variables by other associated conditions, we used highly selective criteria for patient inclusion. First, 
we limited our sample set to singleton pregnancies, and excluded any patients with preexisting hypertension or 
diabetes mellitus. Second, all of our control set (CTRL; n = 6) delivered at term with no other pregnancy com-
plications (such as preterm labor or premature rupture of membranes). Finally, we limited our PE set (n = 11) to 
patients with systolic blood pressures ≥ 140 mm Hg and circulating sFlt1:PlGF ratios ≥ 85, an accepted diagnostic 
measure of PE associated with adverse PE related maternal/fetal outcomes11,32,33. (Fig. 1c and Table 1). Gestational 
delivery week, ranged from 37 to 40 weeks in the CTRL set and from 28 to 39 weeks in the PE set. Based on 
the gestational delivery week, we further divided the PE patients into Early-Onset (EO-PE; gestational delivery 
week < 34; n = 8) and Late-Onset (LO-PE; gestational delivery week > 34; n = 3) subgroups. In all cases, placental 
tissue was collected within 30 minutes of delivery and flash frozen in liquid nitrogen. Using these frozen samples, 
we isolated polyA tailed RNA from the villous tissue, which is the spongy layer in between the decidua (maternal 
side) and the chorion (fetal side), and the main source of sFlt134.
To analyze alternative polyadenylation transcriptome-wide, we developed a simple, kit-free method by com-
bining elements of a published PAS-Seq protocol25 with a circularization strategy used in our lab for making short 
RNA fragment libraries35 (Fig. 2a, see Methods). Single-end sequencing on the Illumina HiSeq. 2000 platform 
yielded 30–70 million (in average) high quality reads per library, of which 70–85% mapped uniquely to the human 
genome (hg19) (Supplementary Table S1). Using a custom pipeline (Fig. 2b and Methods), peaks were identified as 
clusters of ≥ 15 reads (all libraries combined) whose 3′ ends mapped within a 40 nt window (to allow for microhet-
erogeneity in polyadenylation site use)36. Peaks representing true polyadenylation site (i.e., those at which a polyA 
tail was added post-transcriptionally) were distinguished from peaks due to oligoT internal priming of transcripts 
at genomically-encoded adenosine-rich regions using a Naives Bayes classifier based probabilistic method25. True 
polyadenylation site were then assigned to genes using GENCODE (v19) annotations and quantified as counts per 
million (CPM). Custom UCSC genome browser tracks enabled visualization of read clusters and true polyadenyl-
ation site sites (Fig. 2c). In all, we detected 31,615 polyadenylation sites on or within 5 kb downstream of annotated 
transcripts representing 13,328 genes and 3,482 polyadenylation sites in intergenic regions. The majority of the 
annotated set was dominated by protein-coding genes (n = 27,395 PAS; 86.6%), but also contained hundreds of 
small nuclear RNAs, long non-coding RNAs, microRNAs and anti-sense transcripts (Fig. 2d).
By summing all true polyadenylation site reads mapping across individual loci, PAS-Seq data can be used to 
assess overall gene expression. That is, the data can be collapsed into a single gene expression number – counts per 
million mapped reads (CPM) that encompasses all polyadenylated isoforms derived from each gene24. The top 
500 genes in our samples were highly enriched for those expressed in placenta (p ≤ 8.4 e-43) and syncytiotroph-
oblasts (p ≤ 6.5 e-42) (see Methods). Consistent with a previous RNA-Seq report37, nearly all of the 20 most 
highly expressed genes in the CTRL, EO-PE and LO-PE samples (Fig. 3a,b,c) were placental or pregnancy-related 
(Supplementary Table S2). This highest abundance set was dominated by hormones (e.g., CSH1, CSH2 and 
Variables CTRL (n = 6) EO-PE (n = 8) LO-PE (n = 3)
Systolic BP (mmHg) 125 ± 10 183 ± 14*** 154 ± 4**
Diastolic BP (mmHg) 79 ± 8 109 ± 11** 98 ± 15
Maternal plasma sFlt1 (pg/mL) 9238 ± 4257 29672 ± 10420*** 26243 ± 13805*
Maternal plasma PGF (ng/mL) 331 ± 262 98  ± 55* 158 ± 77
sFlt1: PlGF ratio 40 ± 24 405 ± 256*** 166 ± 14*
Maternal age (years) 35 ± 8 31 ± 5 27 ± 6
Maternal pre-pregnancy BMI (kg/m2) 26 ± 5 34 ± 5* 18 ± 8
Gestational delivery week 39 ± 1 31 ± 2*** 37 ± 2
Proteinuria NA 100% 100%
Newborn gender (F/M) 3/3 4/4 2/1
Mode of delivery (C-sec/Vaginal) 6/0 8/0 3/0
Induction of labor (yes/no) 0/6 1/7 2/1
Table 1. PAS-Seq patient characteristics. Mean statistic ± standard deviation. Patient set comparisons were 
performed using the Mann-Whitney test; *P = 0.05, **P = 0.001, ***P = 0.0002.
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CGA), positive and negative regulators of cell growth (e.g., GDF15 and TFPI2) and hemoglobin genes (HBA1, 
HBA2, HBB and HBG2); also included were two high abundance long non-coding RNAs, H19 and NEAT1.
EO-PE and LO-PE placentas exhibit distinct gene expression signatures. To determine whether 
the different patient sets had distinct gene expression patterns, we next performed Principal Component Analysis 
with all detected genes with sufficient read coverage (total read count across all 17 libraries ≥ 10; n = 15,765). By 
assessing variability across all samples independent of any externally imposed subsets, Principal Component 
Analysis (aka PCA) allows one to determine how closely related individual samples are to one another. For the 
top 2000 most variable genes across all libraries, Principal Component(PC) 1, 2 and 3 accounted for 21.8, 15.4 
and 10.4 percent of the variance, respectively. In a plot of Principal Component 1 vs. Principal Component 2, 
Figure 2. PAS-Seq library and bioinformatics workflow. (a) Schematic overview of PAS-Seq library preparation 
workflow. (b). PAS-Seq bioinformatics pipeline schematic. (c) Representative view of read alignment locations 
(top track) and called PAS peaks (bottom track) on the ADAM12 3′-UTR. Our algorithm is able to remove 
background noise, filter out internal priming sites and accurately identify true polyadenylation sites. (d) 
Distribution of PAS peaks among named gene classes and intergenic regions.
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the CTRL samples formed a coherent cluster readily distinguishable from the PE samples (Fig. 3d). Further, the 
EO-PE and LO-PE samples formed distinct but overlapping clusters primarily defined by PC1, with the EO-PE 
cluster being more distant from CTRL than the LO-PE cluster. This suggested that EO-PE and LO-PE had over-
lapping but distinct gene expression signatures.
To define the sets of differentially expressed genes between our three groups, we performed pairwise dif-
ferential gene expression analyses between CTRL, EO-PE and LO-PE using DESeq. 2 (Fig. 3e,f,g). DESeq. 2 
is a software package routinely used to analyze high-throughput PAS-Seq and RNA-Seq datasets38. In agree-
ment with the Principal Component Analysis, the pair exhibiting the greatest differential expression profile 
was between CTRL and EO-PE (n = 701, padj ≤ 0.05). The most highly upregulated gene in EO-PE compared 
to CTRL was FLT1 (4.3-fold up), followed by Myosin 7B (MYO7B, 3.4-fold up) and Endoglin (ENG, 3-fold up). 
Other upregulated genes previously linked to PE included Inhibin Alpha (INHA, 2.8-fold up), Inhibin Beta A 
(INHBA, 2.5-fold up), Vascular Endothelial Growth Factor A (VEGFA, 2.2-fold up), MicroRNA 210 Host Gene 
(MIR210HG, 2.4-fold up) and Pappalysin 2 (PAPPA2, 2.6-fold up). Genes exhibiting the greatest downregulation 
were Somatostatin Receptor Type 1 (SSRT1, 4.3-fold down), Signaling Lymphocytic Activation Molecule Family 
Member 1 (SLAMF1, 4.1-fold down), Hyaluronan And Proteoglycan Link Protein 1 (HAPLN1, 3.2-fold down) 
and Cell Adhesion Molecule 3 (CADM3; 2.8-fold down).
Overall, 349 genes were differentially expressed at a padj ≤ 0.01 between CTRL and EO-PE (Fig. 3e). Using a 
variety of online tools such as GeneCoDis39–41 and Genomatix, we performed extensive gene ontology analyses 
of this set, using all other expressed 13,299 genes as background (Supplementary Table S3). Recurring themes 
(Supplementary Tables S4 and S5) were Biological/Cellular Adhesion and the HIF1 alpha, HIF2 alpha, Interleukin 
6, Angiogenesis, Cadherin, and Wnt signaling pathways, all of which have been previously linked to PE42–44. 
Also enriched were Pol II transcription factors and genes with LEF1 and TATA transcription factor binding sites 
(padj ≤ 0.01).
Consistent with the principal component analysis, fewer genes were differentially expressed between CTRL 
and LO-PE, with only 40 reaching the padj ≤ 0.01 threshold (Fig. 3f). Those exhibiting the greatest fold change 
in LO-PE were Perilipin 2 (PLIN2; 2.1-fold up), Zinc Finger Protein 175 (ZNF175, 2.1-fold up), Acyl-CoA 
Synthetase Long-Chain Family Member 1 (ACSL1, 2.1-fold up), Dual Specificity Phosphatase 15 (DUSP15, 
2.3-fold down) and Forkhead Box S1 (FOXS1, 2.3-fold down). The 97 differentially expressed genes (padj ≤ 0.05; 
13,265 background gene set) were highly enriched for Pol II transcription factors and components of the HIF2 
alpha signaling pathway (Supplementary Tables S3, S6 and S7).
Comparison of the differentially expressed genes in EO-PE and LO-PE revealed that they have overlapping but 
clearly distinct gene expression profiles (Supplementary Fig. S2). Gene ontology terms associated with the 50 dif-
ferentially expressed genes common to both EO-PE and LO-PE (padj ≤ 0.05) includes the HIF1 alpha, HIF2 alpha 
and VEGFR1 (FLT1) signaling pathways (Supplementary Table S8). Differential expression analysis between 
EO-PE and LO-PE sets revealed 19 genes reaching the padj ≤ 0.05 threshold (Fig. 3g), with the genes exhibiting 
the greatest differences being Family With Sequence Similarity 19 Member A2 (FAM19A2, 2.5-fold higher in 
EO-PE), Pleiomorphic Adenoma Gene-Like 2 (PLAGL2, 2.3-fold higher in EO-PE), TNF Receptor Superfamily 
Member 10a (TNFRSF10A, 1.9-fold higher in LO-PE) and HAPLN1 (1.9-fold higher in LO-PE). Thus, while 
EO-PE and LO-PE have similar clinical presentations, their distinct gene expression signatures suggest different 
mechanistic drivers9,10,45.
Comparison to previous differential gene expression studies. Numerous other studies have 
employed microarrays or RNA-Seq to investigate differential gene expression in PE. We therefore compared our 
differentially-expressed EO-PE and LO-PE gene sets (padj ≤ 0.05) to similar gene sets from two recent RNA-Seq 
studies37,46 and a large scale meta analysis of microarray datasets47 (Fig. 3h). As expected from the heterogeneous 
and multifactorial nature of PE, the gene sets reported in the three previous studies were largely non-overlapping 
(Fig. 3h). Our gene lists were most similar to the microarray list47, with 289 of 701 (41%) differentially-expressed 
EO-PE genes and 32 of 97 (33%) differentially-expressed LO-PE genes being among the 1295 genes (padj ≤ 0.01) 
in the microarray set. Notably, only one gene, NRIP1 (nuclear receptor-interacting protein 1; aka RIP140), inter-
sected all five lists (Fig. 3h). Upregulated in all datasets, NRIP1 is a ubiquitously-expressed nuclear protein that 
acts as a co-activator and/or co-repressor for numerous nuclear receptor transcription factors48.
The only other differentially expressed gene reported in all previous studies and ours was FLT1. Although 
FLT1 did not appear in the list of differentially expressed genes in the Kaartokallio et al. study46, it was stated 
in the text as being differentially expressed. The magnitude of FLT1 overexpression in PE varies greatly among 
published reports – whereas the microarray and RNA-Seq values ranged from 1.5 to 2.0-fold37,47, qPCR analyses 
specifically interrogating the FLT1 locus range from 3.86-fold to 4.5-fold above normal16,37. In our PAS-Seq data, 
FLT1 was the most highly upregulated gene in the EO-PE patient set, exhibiting a 4.3-fold increase relative to the 
CTRL set (padj = 2.21E-13; Fig. 3e). FLT1 was also upregulated the LO-PE set, but only by 1.9-fold (padj ≤ 0.01; 
Fig. 3f). Further, consistent with Flt1 overexpression being a significant driver of clinical symptoms, total Flt1 
gene expression strongly correlated with systolic blood pressure over all samples (r = 0.84) (Fig. 3i). Flt1 also 
correlated with body mass index (BMI), but to a much lesser degree (r = 0.51, Supplementary Fig. S2). Thus our 
PAS-Seq data validate previous findings that Flt1 overexpression is central to PE.
Non-coding RNAs and intergenic regions. In addition to protein-coding genes, our PAS-Seq data also 
provided expression values for numerous non-coding RNAs (Supplementary Table S3). For example, many miR-
NAs (miRs) derive from long non-coding polyA + primary transcripts (pri-miRNAs)49. Pri-miRNAs exhibiting 
particularly high placental expression include the chromosome 14 and 19 miR clusters (C14MC and C19MC, 
respectively), the miR-371–3 cluster and the mir210 host gene (mir210HG)50–52. C19MC is transcribed by 
Pol III53, so was not represented in our PAS-Seq data. Of the remaining three, only the mir210HG exhibited 
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Figure 3. Differential gene expression analysis. Box-plots of top twenty most abundant transcripts in (a) CTRL, 
(b) EO-PE, and (c) LO-PE patients. Gene expression measured as Counts Per Million (CPM) mapped reads. 
Dark bar: median; box: 25–75% interquartile; whiskers and dots: range. (d) Principal component analysis 
(PCA) of highly variable genes. Axes are principal components 1 and 2 (PC1 and PC2). Each point represents 
a single patient, with colors indicating the patient type as in Fig. 1a. Volcano plots showing differential gene 
expression for (e) CTRL vs. EO-PE, (f) CTRL vs. LO-PE, and (g) EO-PE vs. LO-PE. X-axis: log2 Fold Change 
(FC) between samples; Y-axis: -log10 false discovery rate after false positive removal (padj). Each dot is a gene: 
purple, padj ≤ 0.01; black, padj ≤ 0.05; n, number of genes in each group. (h) Venn diagram illustrating overlap of 
differentially expressed genes (padj cutoffs as indicated) between our EO-PE and LO-PE PAS-Seq datasets, two 
published RNA-Seq datasets37,46 and a large meta analysis of available microarray data47. (i) Scatter plot of FLT1 
RNA expression (CPM) vs. Systolic Blood Pressure (mmHg). Each point represents a single patient, with colors 
indicating the patient type as in Fig. 1a.
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differential expression among our patient sets, being 2.4 and 1.8-fold increased in EO-PE and LO-PE, respectively, 
relative to CTRL. Previously shown to be upregulated in PE54, miR210 is known to downregulate the THSD7A 
gene55. Consistent with this, THSD7A was 1.5-fold downregulated in EO-PE (padj ≤ 0.043), and 1.3-fold down-
regulated in LO-PE (although not statistically significant; padj ≤ 0.58).
Other differentially expressed noncoding transcripts with embedded miRNAs were DNM3OS (miR214; 
1.7-fold down in both EO-PE and LO-PE) and RP6–99M1.2 (miR221/miR222; 1.6-fold down in EO-PE). Finally, 
some miRNAs derive from the introns or 3′-UTRs of protein coding genes, including SREBF1 (miR33b and 
miR6777; 1.6-fold up in EO-PE, 1.5-fold up in LO-PE), PDCD4 (miR4680; 1.5-fold up in EO-PE), and FAM172A 
(miR2277; 1.4-fold down in EO-PE). Among this set, only miR214 has been previously linked to PE, with 
microarray data indicating its downregulation56. miR214 is thought to regulate both PLGF57 and components of 
the β-catenin pathway58, with its own expression being modulated by HIF1 alpha57.
Our datasets also included polyadenylation sites for 170 long non-coding RNAs, 112 anti-sense transcripts 
and 133 “processed transcripts” (defined in GenCode as a transcript with no open reading frame). Although nine 
of these were differentially expressed in EO-PE, LO-PE or both (Supplementary Table S3), careful examination 
of the associated polyadenylation site peaks on the UCSC genome browser revealed that nearly all could be 
explained by differential expression of an overlapping protein coding gene. Thus we conclude that differential 
long non-coding RNA expression is not a general hallmark of PE. The sole exception was TP73-AS1 (downstream 
of and antisense to TP73, expression of which was undetectable in our dataset), a lowly expressed transcript (base 
mean = 62.5 CPM) that was 1.4 fold-downregulated (padj = 0.02) in EO-PE. TP73-AS1 is differentially expressed 
in multiple cancers59, and recent evidence suggests that it functions to positively regulate expression of BDH2, a 
cytosolic type 2 hydroxybutyrate dehydrogenase involved in mitochondrial function59. While BDH2 expression 
was 1.4-fold reduced in our EO-PE set, this change was not statistically significant (padj = 0.15).
Finally, we examined the 3,482 intergenic polyadenylation sites. Compared to the mean CPM distribution for 
genic PAS, the vast majority of intergenic PAS were lowly expressed (Supplementary Fig. S1), and DESeq. 2 anal-
ysis yielded only 13 and 8 differentially expressed intergenic polyadenylation site in EO-PE and LO-PE, respec-
tively (Supplementary Table S9). Many of these were associated with Long Interspersed Elements (LINEs) and 
Long Terminal Repeat elements (LTRs), suggesting that activation of select endogenous retroviral elements might 
occur in PE. For example, three intergenic PAS upregulated in EO-PE lie between the LTF and CCRL2 genes in 
a region containing numerous retroviral elements, and an RNA-Seq track of multimapping reads confirmed the 
existence of an independent multiple LTR-containing transcript (Supplementary Fig. S1).
All Flt1 isoforms are upregulated in PE. A major goal of this study was to determine which sFlt1 mRNA 
isoform(s) to target with therapeutic siRNAs60 (Turanov et al., in preparation). Our PAS-Seq data revealed a 
total of 16 PAS in the Flt1 gene (Fig. 4b and c; Supplementary Table S10), including all 6 previously reported Flt1 
mRNA isoforms. Thirteen are low abundance, each representing < 0.6% of true PAS reads mapping to the Flt1 
locus. Two previously reported isoforms, sFlt1-i14 (previously sFlt1-v4) and sFlt1-e15b (previously sFlt1-v3), 
were among this low abundance set, so contribute little to sFlt1 expression. The four high abundance species are 
sFlt1-i13S (previously sFlt1_v1 short 3′UTR), sFlt1-i13L (previously sFlt1_v1 long 3′UTR), sFlt1-e15a (previ-
ously sFlt1_v2) and m-Flt1 (membrane-bound or full-length Flt1 mRNA) (Fig. 4a). Among these, sFlt1-e15a is 
the most abundant, accounting for ~50% of Flt1 PAS reads in all samples (Fig. 4b). The sFlt1-i13 short and long 
isoforms each accounted for 20 to 25% of PAS reads, whereas full-length m-Flt1 mRNA represented only ~5% of 
PAS reads. Thus, at time of delivery, sFlt1-i13 short, sFlt1-i13 long and sFlt1-e15a comprise the vast majority (88 
to 97%) of placental Flt1 mRNAs.
Comparison among datasets revealed that all four high-abundance Flt1 isoforms are upregulated in EO-PE vs. 
CTRL (p ≤ 0.05; two-way t-test) (Fig. 5a). A similar trend is also observed comparing LO-PE to CTRL, but only 
the sFlt1-i13 long isoform reached statistical significance (p ≤ 0.05; two-way t-test), likely due to the small sample 
size. To assess whether this general upregulation of the Flt1 locus was accompanied by any shift in PAS usage, 
we examined how the fraction of total reads mapping to each of the four major PAS differed among the EO-PE, 
LO-PE and CTRL datasets (Fig. 5b). The only statistically significant (two-way t-test) differences were a 1.5-fold 
increase in sFlt1-i13 short and a 2.0-fold reduction in mFlt1 in EO-PE compared to CTRL. Thus in EO-PE, use of 
the sFlt1-i13 short PAS increases at the expense of the mFlt1 PAS. Nonetheless, the predominant feature associ-
ated with both EO-PE and LO-PE is transcriptional upregulation of the entire Flt1 locus.
Other genes with altered isoform abundances. The altered Flt1 mRNA isoform abundance associ-
ated with EO-PE prompted us to ask whether this phenomenon was detectable at any other gene loci. Using 
one-vs.-others model (see Methods), we observed PAS switches (padj ≤ 0.05) in only eight genes in EO-PE com-
pared to CTRL (ADAM12, FLT1, NEAT1, TIMP2, CRH, PAPPA, PSAP and SDC1) and only four genes in LO-PE 
compared to CTRL (EIF2A, PSG1, SDC1 and PHLDB2) (Supplementary Table S11), with SDC1 being common 
to both. The switches were almost equally divided between proximal-to-distal (n = 6) and distal-to-proximal 
(n = 5) isoform shifts. Most of the altered isoform abundances were limited to shifts within untranslated regions 
and so were not expected to alter protein isoform ratios. The exceptions were FLT1 (discussed above), SDC1 and 
ADAM12. In all three cases, the affected mRNA isoforms change the ratio of secreted and membrane-bound 
isoforms. The SDC1 gene encodes short (secreted or “shed”) and long (membrane-bound) forms of the major 
transmembrane heparan sulfate proteoglycan syndecan 1 from mRNA isoforms having different PAS (Fig. 5c). In 
both EO-PE and LO-PE, the isoform encoding membrane-bound SDC1 was preferentially upregulated. Likewise, 
ADAM12 expresses two alternate PAS mRNA isoforms, ADAM12-S and ADAM12-L, encoding short (S,secreted) 
and long (L,membrane-bound) forms of metalloproteinase-disintegrin 1261,62 (Fig. 5d). Whereas the entire gene 
is 1.6-fold upregulated in EO-PE, the ADAM12-L isoform increases more than the ADAM12-S isoform (1.8-fold 
vs. 1.3-fold, respectively).
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Discussion
Here we present comprehensive differential gene expression and PAS isoform abundance analysis of placen-
tal RNA from subjects having an abnormal plasma angiogenic profile accompanying either EO-PE or LO-PE. 
We find that EO-PE and LO-PE are distinct conditions with different but related gene expression signatures. 
Common to both is overexpression of the anti-angiogenic factor sFlt1, expression of which strongly correlates 
with systolic blood pressure (Fig. 3i). Our PAS-Seq analysis confirms previous reports identifying sFlt1-e15a as 
the predominant sFlt1 mRNA isoform in both normal and PE placentae20,22,63–65, with the next most abundant 
Figure 4. FLT1 alternative PAS isoform analysis. (a) Schematic of FLT1 gene and six previously identified 
mRNA isoforms arising from alternative polyadenylation. Thick boxes: protein coding exons; thin boxes: 3′-
UTRs; lines: introns; arrows: sFlt1 and mFlt1 polyadenylation sites. Table shows all previous isoform names and 
new systematic names. (b) UCSC genome browser view showing PAS-Seq peak distribution on the FLT1 gene 
for a representative CTRL (top track), EO-PE (middle-track) or LO-PE (bottom track) patient. Arrows: sFlt1 
and mFlt1 polyadenylation sites for isoforms in (a). (c) Bar graph showing mean expression (counts per million; 
CPM) across all libraries for all 16 detected mRNA isoforms at the FLT1 locus.
www.nature.com/scientificreports/
9SCIENTIfIC RepoRts | 7: 12139  | DOI:10.1038/s41598-017-11639-6
isoforms being sFlt1-i13 short and long66. Together sFlt1-i13-short, sFlt1-i13-long and sFlt1-e15a account for 
> 94% of all sFlt1 expression in both normal and PE placentae. This information enabled us to identify siRNAs 
that decrease sFlt1 expression as a potential therapeutic for PE66. Our observation that all Flt1 isoforms increase 
in PE indicates that Flt1 upregulation is primarily a transcriptional response. Intriguingly, the only other gene 
Figure 5. Differential PAS isoform analysis on FLT1, SDC1 and ADAM12 genes. (a) Superimposed scatter 
plots showing expression (counts per million mapped reads; CPM) of the four most abundant FLT1 mRNA 
isoforms. (b) Superimposed scatter plot comparing fractions of total PAS reads mapping to the FLT1 locus 
represented by each indicated mRNA isoform. For a. and b., each point represents an individual CTRL, EO-PE 
or LO-PE patient with the color indicating patient type as described in Fig. 1c. A two-way t-test was used for 
statistical comparisons between indicated groups. Horizontal line: mean; n.s.: not statistically significant. (c) 
UCSC genome browser view of SDC1 gene illustrating differential PAS isoform abundance (Distal-to-Proximal 
Switch) for a representative CTRL (top track), EO-PE (middle-track) or LO-PE (bottom track) patient. (d) Same 
as c, but ADAM12 gene (Proximal-to-Distal Switch).
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differentially expressed in PE across all transcriptome-wide analyses to date is the transcriptional coregulator 
NRIP1 (RIP140)48,67.
Because sFlt1 is a key negative regulator of angiogenesis in both normal68 and cancerous tissues69, how its 
production is modulated has been the topic of multiple studies outside the placenta. One condition known to 
alter sFlt1 expression is hypoxia70,71. In human microvascular endothelial cells (HMVECs), the predominant sFlt1 
mRNA isoform is sFlt1-i13-short. Under hypoxic conditions, sFlt1-i13-short levels decrease, but mFlt1 levels 
are unaffected suggestive of a post-transcriptional mechanism72. More recent work73 identified heterogeneous 
nuclear ribonucleoprotein D (hnRNP D) as a negative regulator of sFlt1-i13-short production, possibly acting 
through binding to an AU-rich element near the sFlt1-i13-short PAS and thereby blocking access of the polyade-
nylation machinery to this location. That study further showed that this inhibitory activity was a function of both 
overall hnRNP D levels and the methylation status of a specific hnRNP D arginine residue. In EO-PE placental 
samples, however, we observed the opposite trend – a small increase in sFlt1-i13 short at the expense of mFlt1 
(Fig. 5b). We also observed no differential gene expression for arginine methyltransferase (PRMT1), arginine 
demethylase (JMJD6), hnRNP D or any other hnRNP protein (data not shown). Thus sFlt1 upregulation in PE 
appears to be mechanistically unrelated to the hypoxia-dependent modulation of sFlt1-i13-short production in 
HMVECs.
Our data clearly show that all FLT1 mRNA isoforms increase in abundance in PE (Fig. 5a), with no gen-
eral shift toward the more promoter proximal PAS (Fig. 5b). When we considered the entire transcriptome, we 
detected no general 3′-UTR shortening (data not shown) and only eleven statistically significant PAS isoform 
abundance changes overall (Supplementary Table S11 and Fig. 5c,d). Among these, there was no consistent 
proximal-to-distal or distal-to-proximal switch pattern. Thus there is no general polyadenylation pattern shift 
associated with PE, and alternative polyadenylation is not a major contributor to sFlt1 upregulation. Rather our 
data indicate that the increased sFlt1 expression in PE is primarily due to increased transcription of the entire 
FLT1 locus.
What is driving this increased FLT1 transcription? Because of its central role in regulating angiogenesis, FLT1 
transcriptional regulation has been intensely investigated in other tissues and several upstream transcription fac-
tors including EPAS1, PAX3, p53 and ETS have been characterized74–79. Notably, the differentially expressed gene 
sets (padj ≤ 0.05) in both EO-PE and LO-PE included numerous Pol II transcription factors. Common to both sets 
were CEBPA, SP3, DLX5, BHLHE40 and SREBF1, all of which had increased expression, and ZEB2, which had 
decreased expression. The CEBPA (CCAAT/enhancer binding protein alpha) pathway is particularly interesting, 
as CEBPA is expressed in the labyrinthine trophoblasts (the same cells that express Flt1) and has been shown to 
regulate placental development80.
Intriguingly, the only other gene identified by every transcriptome-wide gene expression analy-
sis method to date (microarray, RNA-Seq and PAS-Seq) as being differentially expressed in PE is NRIP1 
(nuclear receptor-interacting protein 1; aka RIP140) (Fig. 2h). In all cases, NRIP1 was upregulated. A 
ubiquitously-expressed nuclear protein, NRIP1 modulates the activities of numerous nuclear receptor transcrip-
tion factors48. Its best understood role is as a regulator of energy expenditure in adipose and muscle tissues, but 
it has also been linked to ovarian fertility and maintenance of a pregnancy state81. Whether NRIP1 contributes to 
the metabolic syndrome often associated with PE or it directly regulates sFlt1 expression remains to be explored. 
We note that NRIP1 has been implicated in the pathogenesis of obesity48,67a major risk factor for PE. It is possible 
that upregulated NRIP1 may synergize with anti-angiogenic factors to induce the endothelial dysfunction ulti-
mately leading to PE.
Previous microarray studies comparing samples from patients with HELLP syndrome (a particularly severe 
form of PE associated with hemolysis, elevated liver enzymes and low platelet count) to EO-PE and/or LO-PE 
with CTRL patients, found that these are discrete conditions with distinct gene expression signatures and dif-
ferent mechanistic drivers9,10,45. Our PAS-Seq data are consistent with these previous findings. We found many 
more differentially expressed genes in the EO-PE cohort than in the LO-PE cohort, although the small size of 
our LO-PE dataset (n = 3) may have precluded all but the most consistently differentially expressed genes from 
reaching statistical significance. An additional caveat is that some gene expression differences could be due to ges-
tational age differences, particularly between the EO-PE (gestational delivery week < 34) and CTRL (gestational 
delivery week >37–40) groups. Nonetheless the HIF1 alpha, HIF2 alpha and VEGFR1 (FLT1) signaling pathways 
were differentially expressed in both groups, consistent with hypoxia and altered angiogenesis being generally 
associated with PE82–85. But unique to the EO-PE set were genes involved in Biological/Cellular Adhesion and the 
Interleukin 6, Cadherin, and Wnt signaling pathways. This suggests that EO-PE placentae may have defects in 
epithelial to mesenchymal transition which may lead to defective trophoblast invasion noted in this syndrome86.
Due to its highly heterogeneous presentation, definitive diagnosis of PE based solely on maternal signs and 
symptoms can be erroneous87,88. A variety of underlying conditions can serve as mechanistic drivers, confounding 
gene expression analysis of diverse patient populations. Differences in sample collection methodologies across 
institutions can also introduce variability. These factors likely explain the relatively poor overlap among prior 
transcriptome-wide analyses of placental gene expression in PE (Supplementary Fig. S2). For the current study, 
we aimed to eliminate as many variables as possible. In addition to using highly selective criteria for PE diagnosis 
based solely on quantitative measures (Fig. 1c) and excluding known confounding drivers (e.g., multi-parity, 
preexisting hypertension and gestational diabetes mellitus), all samples were collected by the same personnel in 
a single hospital, all libraries were prepared by a single researcher, and all sequencing was performed on a single 
instrument. Our libraries should thus represent highly coherent sets. Nonetheless, our study does have its own 
limitations. Because all but one PE subject delivered at ≤ 36 weeks gestational age, whereas all CTRL patients 
delivered closer to term (≥ 37 weeks), PE and CTRL placentas were not gestationally matched. Therefore, addi-
tional studies using placentas delivered for other medical reasons (e.g., preterm labor) will be needed to evaluate 
which gene expression changes, if any, are simply attributable to earlier gestational age in the PE subjects. As 
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stated above, our study was also limited by small sample size particularly for the LO-PE group (n = 3). Future 
studies with adequate sample numbers are needed to fully characterize the transcriptional signature specific to 
LO-PE.
In addition to assessing protein-coding genes, we interrogated our PAS-Seq data with regard to non-coding 
and intergenic transcripts. While we found little evidence of differential long non-coding RNA expression in PE, 
our data do suggest a potential association between EO-PE and endogenous retroviral element activation. Thus it 
may be of interest to interrogate repeat-associated transcripts in existing PE placental RNA-Seq datasets37,46. Our 
PAS-Seq data also confirm upregulation of miR210 and downregulation of miR214 in PE54. Therefore, some gene 
expression differences associated with PE are likely driven by post-transcriptional mechanisms.
Methods
Ethics Statement. The study was approved by the Beth Israel Deaconess Medical Center Institutional 
Review Board (IRB), #2008P-000061. All subjects provided written informed consent for use of placental and 
blood samples for research.
Human subjects. Placentas were collected from normal(CTRL) and PE subjects (Table 1) in accordance 
with all institutional policies and with approval of the institutional review board at the Beth Israel Deaconess 
Medical Center (Boston, MA, USA). The diagnosis of PE was based on the updated criteria of American College 
of Obstetrician and Gynecology Task force on Hypertension in Pregnancy89. Patients with history of diabetes, 
chronic hypertension, renal disease or multiple gestations were excluded. Pre-delivery maternal plasma samples 
were used to measure circulating sFlt1 and PlGF using commercial ELISA kits (R & D systems, MN) as described 
elsewhere90.
Tissue collection, storage and RNA isolation. We excised placental biopsies (2 × 2 cm) without basal 
and chorionic plates and wiped with cotton gauze to remove blood and debris. The villous tissue, the spongy layer 
that is in between the decidua (maternal side) and the chorion (fetal side) was collected since it is the main source 
of sFlt134. These tissue samples were flash-frozen in liquid nitrogen within 30 min of placental delivery.
PAS-Seq library preparation and sequencing. For preparation of PAS-Seq libraries, we adapted a pre-
viously published method for making libraries from RNA fragments91; (Fig. 2a). Total RNA integrity was first 
confirmed by agarose electrophoresis (data not shown) and then polyA + RNA enriched by oligoT hybridization. 
PolyA + RNA samples were then fragmented to 60–80 nt via chemical hydrolysis and reverse transcribed with 
one of twelve anchored oligoT oligonucleotides containing forward and reverse Illumina sequencing primer sites 
separated by a hexa-ethyleneglycol spacer (Sp18) linker. At the 5′ end, each oligonucleotide began with 5′p-GG 
to promote ligation91, followed by 5 random nucleotides (unique molecular index, UMI) to enable PCR duplicate 
removal. Each primer also harbored a unique 5 nt Hamming barcode (BC), allowing for sample multiplexing. 
Following cDNA circularization with CircLigase I, libraries were PCR amplified (12–14 cycles) and subjected to 
single end 100 nt sequencing on the Illumina HiSeq platform in the UMass Medical School Deep Sequencing 
Core.
PAS-Seq Bioinformatics analysis. After confirming overall library quality with FASTQC (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/, S.Andrews, 2011), we removed duplicate reads with the same 
UMI. We then used Cutadapt92 to trim residual adaptor/spacer sequences and poly-A stretches from read 3′ ends 
and mapped the reads to hg19 reference genome using Bowtie2 (with parameters –m –best –p4). Only uniquely 
mapping reads with high quality scores (>20) were used for further analysis. Such reads represented 70–85% of 
total reads for all libraries.
We defined the polyadenylation cleavage site as the base closest to the poly-A stretch captured within read 
sequence, thus, very last base at the 3′-end site after the trimming. Based on this, we calculated read coverages of 
every genomic location considering only 3′-end of the aligned reads. This forms a sharp peak of read coverage 
around the cleavage sites with an average width 40nt (ranging between 1nt-120nt). We then clustered sites that are 
in proximity closer than 40nt window and summed the counts of clustered sites. In order to determine all possible 
polyadenylation sites, which might possibly differ from sample to sample, we pooled all candidate locations of 
all samples and reiterated the clustering using the same window length. Since genomic DNA containing poly-A 
stretches can be hybridized and pulled with the oligo-T primers, aka internal priming, we used a Naïve Bayes 
classifier93 based software to determine the likelihood of all sites being false priming sites. In addition to filtering 
internal priming locations based on this, we also removed background noise caused by widespread base level read 
alignments by fitting the count distribution of each gene to Poisson distribution. After determining precise PA 
locations, we then calculated expression/read counts of every PAS for each sample and annotated using Gencode 
v19. We also marked known polyA sites with PolyA DB (http://exon.umdnj.edu/polya_db/). For differential gene 
expression tests, we used sum of all PAS counts of each gene and calculated library sizes based on this. The 
raw read counts for genes were used as an input for differential gene expression analyses using DESeq. 238 in R 
(https://www.R-project.org). The default normalization using ‘estimateSizeFactors’ function was used. Adjusted 
p-values were calculated using the Benjamini and Hochberg method94. In order to determine significance levels 
of alternative polyA site switches, we constructed a 2 by 2 contingency table composed of mean normalized read 
counts of one site and the mean of rest of the sites, if there are multiple, in each of the condition. We tested the sig-
nificance with Chi-square test for given site and iterated through all sites of the gene. We then corrected p-values 
for multiple hypotheses testing using Benjamini and Hochberg method94.
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